The management of intraductal papillary mucinous neoplasm (IPMN) continues to evolve. In
particular, the indications for resection of branch duct IPMN have changed from early …

Background & Aims It is not clear how best to manage patients with low-risk intraductal
papillary mucinous neoplasms (IPMNs) of the pancreas because little is known about IPMN …

Objective To evaluate mid-term outcomes and predictors of survival in non-operated patients
with pancreatic intraductal papillary mucinous neoplasms (IPMNs) with worrisome features …

Objectives: This study evaluated individual risks of malignancy and proposed a nomogram
for predicting malignancy of branch duct type intraductal papillary mucinous neoplasms (BD …

Pancreatic ductal adenocarcinoma (PDA), one of the most lethal cancers worldwide, is
associated with two main types of morphologically distinct precursors—pancreatic …

Introduction The risk of malignancy in branch duct intraductal papillary mucinous neoplasia
of the pancreas (BD-IPMN) is controversially debated. An increasing number of studies …

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease that lacks effective
biomarkers for early detection. We hypothesized that circulating long non-coding RNAs …

Pancreatic cysts, especially incidental asymptomatic ones seen on noninvasive imaging
such as CT or MR imaging, remain a clinical challenge. The etiology of such cysts may …

Purpose To compare diagnostic performance for prediction of malignant potential in IPMNs
between EUS, contrast-enhanced CT and MRI. Materials and methods 76 patients with …

Intraductal papillary mucinous neoplasms (IPMN) are cystic neoplasms with the potential for
progression to pancreatic cancer. Recognized by the global medical community just over …